To include your compound in the COVID-19 Resource Center, submit it here.

Regulatory milestones

Cadence Pharmaceuticals Inc. (NASDAQ:CADX) lost $1.16 (11%) to $9.34 last week after FDA issued a complete response letter for an NDA for Ofirmev IV acetaminophen to manage pain and reduce fever (see B9).

Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) fell $0.42 (40%) to $0.64 on Monday after FDA posted briefing documents indicating the company had not met the statistical hurdle in its trial of Pixuvri pixantrone. FDA also said the company's decision to stop the Phase III PIX301 trial early invalidated the company's SPA (see Online Links, A20).

The documents were posted ahead of an Oncologic Drugs Advisory Committee (ODAC) meeting scheduled for last Wednesday, which

Read the full 1045 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers